Publications by authors named "Jonathan Schapiro"

Claim this Profile
L
Lenacapavir-associated drug resistance: implications for scaling up long-acting HIV pre-exposure prophylaxis.
Gert van Zyl, Mateo Prochazka, Heather-Marie Ann Schmidt, Catherine Orrell, Jonathan M Schapiro

Lancet HIV· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emergent Human Immunodeficiency Virus Type 1 (HIV-1) Drug Resistance in Randomized Trials of Contemporary Antiretroviral Regimens.
Josep M Llibre, Diego Ripamonti, Anna M Geretti, Raquel Martin-Iguacel, Paul E Sax, Jonathan M Schapiro

Clin Infect Dis· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of antiretroviral regimen switching options in adults with HIV with sustained viral load non-suppression on dolutegravir, lamivudine, and tenofovir in eastern, central, southern, and western Africa: a modelling study.
Andrew N Phillips, Loveleen Bansi-Matharu, Joep J van Oosterhout, Emily Hyle, David van de Vijver, Jonathan Schapiro

Lancet HIV· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Noncanonical HIV drug resistance mutations: need to close existing gaps.
Seth Inzaule, Michael R Jordan, Joseph Fokam, Raph L Hamers, Roger Paredes, Jonathan Schapiro

AIDS· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fostemsavir resistance in clinical context: a narrative review.
Jonathan M Schapiro, Rolf Kaiser, Mark Krystal, Chris M Parry, Allan R Tenorio

Ther Adv Infect Dis· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiometabolic health in people with HIV: expert consensus review.
Rachel L Batterham, Roger J Bedimo, Ricardo S Diaz, Giovanni Guaraldi, Janet Lo, Jonathan M Schapiro

J Antimicrob Chemother· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Expanded Multivariable Models to Assist Patient Selection for Long-Acting Cabotegravir + Rilpivirine Treatment: Clinical Utility of a Combination of Patient, Drug Concentration, and Viral Factors Associated With Virologic Failure.
Chloe Orkin, Jonathan M Schapiro, Carlo F Perno, Daniel R Kuritzkes, Parul Patel

Clin Infect Dis· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recommendations on data sharing in HIV drug resistance research.
Seth C Inzaule, Mark J Siedner, Susan J Little, Santiago Avila-Rios, Alisen Ayitewala, Jonathan M Schapiro

PLoS Med· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dynamics of Human Immunodeficiency Virus Type 1 A6 Variant Transmissions Between Poland and Ukraine.
Jonathan M Schapiro

Clin Infect Dis· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A systematic review of adeno-associated virus gene therapy clinical trials for HIV - A potential solution for patients with haemophilia and HIV?
Sarina Levy-Mendelovich, Christopher E Walsh, Jonathan M Schapiro, Shelly Soffer, Eyal Klang

Haemophilia· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study.
Jennifer Smith, Loveleen Bansi-Matharu, Valentina Cambiano, Dobromir Dimitrov, Anna Bershteyn, Jonathan Schapiro

Lancet HIV· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance.
Soo-Yon Rhee, Jonathan M Schapiro, Francesco Saladini, Maurizio Zazzi, Saye Khoo

AIDS Res Ther· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatment-limited individuals living with HIV.
Chloe Orkin, Pedro Cahn, Antonella Castagna, Brinda Emu, P Richard Harrigan, Jonathan Schapiro

HIV Med· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.
Amy G Cutrell, Jonathan M Schapiro, Carlo F Perno, Daniel R Kuritzkes, Romina Quercia

AIDS· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Emicizumab prophylaxis in haemophilia patients older than 50 years with cardiovascular risk factors: Real-world data.
Mudi Misgav, Tami Brutman-Barazani, Ivan Budnik, Einat Avishai, Jonathan Schapiro

Haemophilia· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The challenging pathway towards the identification of SARS-CoV-2/COVID-19 therapeutics.
Marco Siccardi, Jonathan Schapiro, Giovanni Di Perri, David J Back

J Antimicrob Chemother· September 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug level testing as a strategy to determine eligibility for drug resistance testing after failure of ART: a retrospective analysis of South African adult patients on second-line ART.
Lucas E Hermans, Kim Steegen, Rob Ter Heine, Rob Schuurman, Hugo A Tempelman, Jonathan M Schapiro

J Int AIDS Soc· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrase strand transfer inhibitor (INSTI)-resistance mutations for the surveillance of transmitted HIV-1 drug resistance.
Philip L Tzou, Soo-Yon Rhee, Diane Descamps, Dana S Clutter, Bradley Hare, Jonathan M Schapiro

J Antimicrob Chemother· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cure of chronic hepatitis C virus infection in an HIV-coinfected patient with multiple comorbidities and drug interaction challenges.
Hortensia Álvarez, Ana Mariño, Nieves Valcarce, Saye Khoo, Sanjay Bhagani, Jonathan Schapiro

Int J STD AIDS· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Collaborative update of a rule-based expert system for HIV-1 genotypic resistance test interpretation.
Roger Paredes, Philip L Tzou, Gert van Zyl, Geoff Barrow, Ricardo Camacho, Jonathan M Schapiro

PLoS One· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection.
Kay Seden, Sara Gibbons, Catia Marzolini, Jonathan M Schapiro, David M Burger

PLoS One· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration.
Soo-Yon Rhee, Vici Varghese, Susan P Holmes, Gert U Van Zyl, Kim Steegen, Jonathan M Schapiro

EBioMedicine· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HIV-1 Drug Resistance Mutations: Potential Applications for Point-of-Care Genotypic Resistance Testing.
Soo-Yon Rhee, Michael R Jordan, Elliot Raizes, Arlene Chua, Neil Parkin, Jonathan M Schapiro

PLoS One· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacokinetics and pharmacodynamics of dolutegravir used as a single tablet regimen for the treatment of HIV-1 infection.
Pauline Bollen, Peter Reiss, Jonathan Schapiro, David Burger

Expert Opin Drug Saf· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approach.
Mohammed Lamorde, Jonathan M Schapiro, David Burger, David J Back

AIDS· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis